NLRC4 and macrophage activation syndrome: Although the underlying mechanisms of biallelic NLRC4 deficiency remain elusive, IL-18 blockade was shown to be effective in treatment of NLRC4-mediated macrophage activation syndrome indicating that epithelial-derived IL-18 might be a critical pathomechanistic driver (105).